A detailed history of Allworth Financial LP transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Allworth Financial LP holds 488 shares of VKTX stock, worth $32,144. This represents 0.0% of its overall portfolio holdings.

Number of Shares
488
Previous 482 1.24%
Holding current value
$32,144
Previous $25,000 20.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$49.84 - $70.47 $299 - $422
6 Added 1.24%
488 $30,000
Q2 2024

Jul 23, 2024

BUY
$47.39 - $80.2 $710 - $1,203
15 Added 3.21%
482 $25,000
Q1 2024

Apr 25, 2024

BUY
$17.4 - $94.5 $1,165 - $6,331
67 Added 16.75%
467 $38,000
Q4 2023

Jan 24, 2024

BUY
$9.24 - $19.64 $3,612 - $7,679
391 Added 4344.44%
400 $7,000
Q3 2023

Oct 31, 2023

BUY
$10.92 - $16.0 $98 - $144
9 New
9 $0

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $5.05B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Allworth Financial LP Portfolio

Follow Allworth Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Allworth Financial LP with notifications on news.